Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Standard ADT (androgen deprivation therapy), ADT, ADT (Standard of Care)
Standard ADT · 1 trial · 1 indication
Rate of grade 3-5 AEs, followed by rate of neutropenia grade 3/4 + grade 5 AEs t
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 6 x Docetaxel 75 mg/m2 every 3 weeks of a 3 week cycle Co-administration of docetaxel, darolutamide and standard ADT |
| Arm 2 | EXPERIMENTAL | 6 x Docetaxel 50 mg/ m2 every 2 weeks of a 4 week cycle Co-administration of docetaxel, darolutamide and standard ADT |
| Name | Type | Description |
|---|---|---|
| Standard ADT (androgen deprivation therapy) | DRUG | as prescribed by the treating physician. |
| Standard Darolutamide | DRUG | 2x600 mg/d as prescribed by the treating physician |
| Docetaxel | DRUG | Docetaxel |
Inclusion Criteria: * Written informed consent * Males ≥18 years of age * Histologically or cytologically confirmed adenocarcinoma of prostate * Investigator assessed metastatic disease documented either by a positive bone scan, or for soft tissue or visceral metastases, either by contrast-enhanced...
Standard ADT, or androgen deprivation therapy, is used to treat Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). It is being studied in a Phase 3 clinical trial in combination with darolutamide and docetaxel to evaluate different docetaxel dosing schedules in patients with this condition.
Standard ADT targets androgen receptor signaling by reducing androgen production, which is a key driver of prostate cancer growth. In the context of mHSPC, it is used as a backbone therapy combined with other agents like darolutamide and docetaxel to suppress tumor progression.
Standard ADT is developed by Bayer AG, a multinational pharmaceutical company. The company is conducting a Phase 3 clinical trial to evaluate the combination of Standard ADT with darolutamide and docetaxel in patients with Metastatic Hormone-Sensitive Prostate Cancer.
Standard ADT is in Phase 3 clinical development. It is being evaluated in an active, not recruiting trial (NCT05676203) that compares two docetaxel dosing schedules in combination with darolutamide and ADT in patients with Metastatic Hormone-Sensitive Prostate Cancer.
Standard ADT is being studied in the Phase 3 trial NCT05676203, titled 'A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients'. This randomized, double-blind, active-controlled trial enrolls 250 male patients aged 18 years and older in Austria and Germany.
Yes, Standard ADT is the same as ADT, which stands for androgen deprivation therapy. It is also referred to as ADT (Standard of Care). This therapy is a standard treatment option for prostate cancer and is being tested in combination with other drugs in the mHSPC setting.